Tvardi Therapeutics (TVRD) Depreciation & Amortization (CF) (2016 - 2025)
Tvardi Therapeutics' Depreciation & Amortization (CF) history spans 13 years, with the latest figure at $24000.0 for Q4 2025.
- On a quarterly basis, Depreciation & Amortization (CF) changed 0.0% to $24000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $95000.0, a 0.0% change, with the full-year FY2025 number at $95000.0, changed 0.0% from a year prior.
- Depreciation & Amortization (CF) hit $24000.0 in Q4 2025 for Tvardi Therapeutics, roughly flat from $24000.0 in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for TVRD hit a ceiling of $82000.0 in Q4 2023 and a floor of $5000.0 in Q2 2024.
- Historically, Depreciation & Amortization (CF) has averaged $49736.8 across 5 years, with a median of $60000.0 in 2023.
- Biggest five-year swings in Depreciation & Amortization (CF): crashed 91.67% in 2024 and later surged 840.0% in 2025.
- Tracing TVRD's Depreciation & Amortization (CF) over 5 years: stood at $62000.0 in 2021, then decreased by 1.61% to $61000.0 in 2022, then skyrocketed by 34.43% to $82000.0 in 2023, then plummeted by 70.73% to $24000.0 in 2024, then changed by 0.0% to $24000.0 in 2025.
- Business Quant data shows Depreciation & Amortization (CF) for TVRD at $24000.0 in Q4 2025, $24000.0 in Q3 2025, and $47000.0 in Q2 2025.